Drugs / C-CAR011
C-CAR011
also known as
Anti-CD19 chimeric antigen receptor T cells (C- CAR011)
Cell therapy targets CD19
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03483688 | Mar 2018 → Dec 2019 | B-cell non-Hodgkin lymphoma | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 1 | NCT03299738 | Dec 2017 → Dec 2018 | B-cell non-Hodgkin lymphoma | Shanghai AbelZeta Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03154775 | May 2017 → Apr 2018 | non-Hodgkin lymphoma | Shanghai AbelZeta Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03018093 | Jan 2017 → Aug 2018 | acute lymphoblastic leukemia | Shanghai AbelZeta Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02976857 | Dec 2016 → Sep 2018 | diffuse large B-cell lymphoma | Shanghai AbelZeta Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03327285 | Mar 2018 → Feb 2021 | acute lymphoblastic leukemia | Peking University People's Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C-CAR011 | “C-CAR011 is a safe treatment option for R/R B-NHL” PMID 34362494 ↗ Aug 2021 |
| Known as | Anti-CD19 chimeric antigen receptor T cells (C- CAR011) | “Anti-CD19 chimeric antigen receptor T cells (C- CAR011)” NCT03483688 ↗1“Anti-CD19 chimeric antigen receptor T cells (C-CAR011)” NCT03327285 ↗ |
| Modality | Cell therapy | “Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment” NCT02976857 ↗ |
| Route | Intravenous | “CAR011 cells will be intravenous infused” NCT03018093 ↗ |
| Target | CD19 | “lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene.” NCT02976857 ↗ |